DNA vs. HYFM
DNA (Ginkgo Bioworks Holdings, Inc.) and HYFM (Hydrofarm Holdings Group, Inc.) are both stocks. DNA operates in Biotechnology (Healthcare), while HYFM operates in Farm & Heavy Construction Machinery (Industrials). Over the past 5 years, DNA returned -54.41%/yr vs -72.17%/yr for HYFM. At a 0.29 correlation, their price movements are largely independent.
Performance
DNA vs. HYFM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DNA achieves a -5.05% return, which is significantly higher than HYFM's -38.90% return.
DNA
- 1D
- -1.38%
- 1M
- 2.33%
- YTD
- -5.05%
- 6M
- -15.52%
- 1Y
- -11.74%
- 3Y*
- -53.33%
- 5Y*
- -54.41%
- 10Y*
- —
HYFM
- 1D
- -2.87%
- 1M
- -7.74%
- YTD
- -38.90%
- 6M
- -55.64%
- 1Y
- -71.26%
- 3Y*
- -54.04%
- 5Y*
- -72.17%
- 10Y*
- —
DNA vs. HYFM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
DNA Ginkgo Bioworks Holdings, Inc. | -5.05% | -15.38% | -85.47% | 0.00% | -79.66% | -21.68% |
HYFM Hydrofarm Holdings Group, Inc. | -38.90% | -73.97% | -36.78% | -40.81% | -94.52% | -52.92% |
Correlation
The correlation between DNA and HYFM is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021 | 0.29 |
Over the past year, the correlation between DNA and HYFM has dropped to 0.09 - well below their long-term average of 0.29, suggesting their price drivers have been diverging.
Fundamentals
DNA:
$469.96M
HYFM:
$4.40M
DNA:
-$5.40
HYFM:
-$61.90
DNA:
3.65
HYFM:
0.04
DNA:
$121.84M
HYFM:
$122.24M
DNA:
$99.27M
HYFM:
$10.17M
DNA:
-$218.90M
HYFM:
-$21.47M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DNA vs. HYFM — Risk / Return Rank
DNA
HYFM
DNA vs. HYFM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Hydrofarm Holdings Group, Inc. (HYFM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DNA | HYFM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.58 | ||
| Sortino ratioReturn per unit of downside risk | +1.71 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 0.85 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | -0.23 | -0.88 | +0.65 |
| Martin ratioReturn relative to average drawdown | -0.39 | -1.29 | +0.90 |
Loading charts...
Drawdowns
DNA vs. HYFM - Drawdown Comparison
The maximum DNA drawdown since its inception was -99.10%, roughly equal to the maximum HYFM drawdown of -99.92%. Use the drawdown chart below to compare losses from any high point for DNA and HYFM.
Loading charts...
Drawdown Indicators
| DNA | HYFM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.10% | -99.92% | +0.82% |
Max Drawdown (1Y)Largest decline over 1 year | -66.05% | -83.04% | +16.99% |
Max Drawdown (3Y)Largest decline over 3 years | -94.72% | -95.07% | +0.35% |
Max Drawdown (5Y)Largest decline over 5 years | -99.10% | -99.87% | +0.77% |
Current DrawdownCurrent decline from peak | -98.68% | -99.90% | +1.22% |
Average DrawdownAverage peak-to-trough decline | -79.88% | -86.28% | +6.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.10% | 56.84% | -17.74% |
Volatility
DNA vs. HYFM - Volatility Comparison
Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 21.11% compared to Hydrofarm Holdings Group, Inc. (HYFM) at 13.24%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than HYFM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DNA | HYFM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.11% | 13.24% | +7.87% |
Volatility (6M)Calculated over the trailing 6-month period | 70.92% | 75.85% | -4.93% |
Volatility (1Y)Calculated over the trailing 1-year period | 97.64% | 100.30% | -2.66% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 97.78% | 94.62% | +3.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 96.33% | 94.52% | +1.81% |
Dividends
DNA vs. HYFM - Dividend Comparison
Neither DNA nor HYFM has paid dividends to shareholders.
Financials
DNA vs. HYFM - Financials Comparison
This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Hydrofarm Holdings Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
DNA and HYFM have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DNA has higher volatility (21.11%) compared to HYFM (13.24%). In terms of maximum drawdown, DNA dropped -99.10% vs HYFM's -99.92%.
DNA currently has the higher Sharpe Ratio (-0.16 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DNA and HYFM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer